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Skeletal muscle is a major mass peripheral tissue that
accounts for 40% of total body weight and 50% of en-
ergy expenditure and is a primary site of glucose dis-
posal and fatty acid oxidation. Consequently, muscle
has a significant role in insulin sensitivity, obesity, and
the blood-lipid profile. Excessive caloric intake is
sensed by the brain and induces -adrenergic receptor
(-AR)- mediated adaptive thermogenesis. -AR null
mice develop severe obesity on a high fat diet. However,
the target gene(s), target tissues(s), and molecular
mechanism involved remain obscure. We observed that
30–60 min of -AR agonist (isoprenaline) treatment of
C2C12 skeletal muscle cells strikingly activated (>100-
fold) the expression of the mRNA encoding the nuclear
hormone receptor, Nur77. In contrast, the expression of
other nuclear receptors that regulate lipid and carbohy-
drate metabolism was not induced. Stable transfection
of Nur77-specific small interfering RNAs (siNur77) into
skeletal muscle cells repressed endogenous Nur77
mRNA expression. Moreover, we observed attenuation
of gene and protein expression associated with the reg-
ulation of energy expenditure and lipid homeostasis, for
example AMP-activated protein kinase 3, UCP3, CD36,
adiponectin receptor 2, GLUT4, and caveolin-3. Attenu-
ation of Nur77 expression resulted in decreased lipo-
lysis. Finally, in concordance with the cell culture
model, injection and electrotransfer of siNur77 into
mouse tibialis cranialis muscle resulted in the repres-
sion of UCP3 mRNA expression. This study demon-
strates regulatory cross-talk between the nuclear hor-
mone receptor and -AR signaling pathways. Moreover,
it suggests Nur77modulates the expression of genes that
are key regulators of skeletal muscle lipid and energy
homeostasis. In conclusion, we speculate that Nur77
agonists would stimulate lipolysis and increase energy
expenditure in skeletal muscle and suggest selective ac-
tivators of Nur77 may have therapeutic utility in the
treatment of obesity.
Obesity and fat deposition are primarily controlled by food
intake and energy expenditure. Obesity has been linked to the
development of heart disease, cancer, and stroke, the top three
causes of death in the United States, and has recently been
recognized by the World Health Organization as one of the top
10 global health problems. Moreover, obesity leads to metabolic
syndrome X, a disorder that includes elevated levels of triglyc-
erides and low density lipoprotein (bad) cholesterol, low levels
of high density lipoprotein (good) cholesterol, impaired fasting
glucose, and hypertension (2). These are cardiovascular risk
factors for diseases such as atherosclerosis and type II diabe-
tes. More than 65% of United States adults are overweight, and
30% of adults (greater than 61 million people) are clinically
obese (1, 2).
Diet, lifestyle, metabolism, and genetics are the most signif-
icant factors in controlling weight. Current obesity therapies
perform modestly and are aimed at central appetite suppres-
sion and reduced fat absorption. Recent research suggests that
therapeutic strategies which control satiety, reduce cellular
energy stores, and increase adaptive thermogenesis and lipid
catabolism provide new hope in the quest for novel anti-obesity
drugs (1, 2).
Mechanisms exist that sense dietary excess and trigger
increases in energy expenditure in an effort to preserve the
fat mass set point. This process is responsive to cold and diet
and results in the uncoupling of fuel oxidation from ATP
synthesis, with the energy/proton gradient released in the
form of heat rather than ATP production and is, thus, termed
“adaptive thermogenesis.”
Known components of the energy expenditure system in-
clude leptin, leptin receptor, -melanocyte-stimulating hor-
mone, melanocortin-4 receptor, and the -adrenergic receptors
(-ARs).1 However, many questions remain unanswered, in-
cluding the hardwiring of the central neural circuits regulating
energy balance, the efferent pathways, target tissues, target
genes, and intracellular mechanisms involved (Refs. 3 and 4
and references therein).
The sympathetic nervous system (SNS) is an important ef-
ferent pathway that has been implicated in the control of
adaptive thermogenesis. The evidence includes the following.
Cold and diet induce increases in SNS activity, epinephrine
stimulates energy expenditure, brown fat (a thermogenic tar-
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get tissue) is heavily innervated by the SNS, and thermogenic
activity is dependent on an intact SNS. -ARs and agonists
transmit the thermogenic signals to peripheral tissues and
mediate SNS activity (for review, see Refs. 3–5). Based on the
above findings, a model has been proposed by Lowell and
Bachman (3) that highlights the key aspects of adrenergic-
induced thermogenesis: diet3 brain3 SNS3 -ARs3 target
tissue 3 thermogenesis.
The uncoupling proteins (UCP1–3) allow proton “leakage”
across the inner mitochondrial membrane for the purpose of
heat generation at the expense of coupled ATP production. The
mechanism of adaptive thermogenesis in response to cold ex-
posure has been elucidated and involves UCP1, which is highly
expressed in brown fat. Knock-out experiments in rodents have
demonstrated that UCP1 and brown fat mediate cold-induced
thermogenesis; however, these animals are not obese and are
resistant to diet-induced obesity (6). Knock-out mouse models
of the UCP1 homologs, UCP2 and -3 (which are expressed in
white adipose and skeletal muscle), have not provided clarifi-
cation for a role in maintaining energy expenditure in that
their responses to cold and high fat feeding are normal, and
they show normal body weight and cold tolerance (for review,
see Refs. 3 and references therein; Refs. 7–10). However, some
resolution and understanding of the potential mechanisms con-
trolling diet-induced thermogenesis has come from -AR-less
mice that are obese and completely lack both cold and diet-
induced thermogenesis, indicating that -AR play a role in both
responses (5). However, identification of the target tissues rel-
evant to diet-induced thermogenesis has remained elusive, and
the possibilities include skeletal muscle, white adipose tissue,
and liver, all of which are innervated by the SNS (3, 5).
Skeletal muscle is one of the most metabolically demanding
major mass peripheral tissues that accounts for 50% of energy
expenditure. Moreover, this lean tissue relies heavily on fatty
acids as an energy source, accounts for 75% of glucose disposal,
and is involved in cholesterol efflux. Consequently, muscle has
a significant role in insulin sensitivity and the blood-lipid pro-
file. These facts alone suggest that muscle has an important
role in obesity and suggest muscle may have an important role
in diet-induced modulation of energy expenditure.
The orphan nuclear hormone receptor NR4A subgroup is
expressed in skeletal muscle, and intriguingly, NR4A1/Nur77
induction by -AR agonists has been described in a single
report (11). As mentioned above, the -AR pathways have been
implicated in responses to diet-induced thermogenesis. More-
over, skeletal muscle is rapidly emerging as a critical target
tissue in the battle against obesity (12, 13), metabolic syn-
drome X (14), type II diabetes (15), and dyslipidemia (12–
14,16). Nuclear hormone receptors (NRs) in skeletal muscle, for
example LXR (17) and PPAR (18), -/ (14) and - (15), have
been shown to be involved in enhancing insulin-stimulated
glucose disposal rate, decreasing triglycerides, and increasing
lipid catabolism, cholesterol efflux, and plasma high density
lipoprotein C levels. Hence, understanding the link between
the Nur77 orphan nuclear receptor, the -adrenergic response,
and energy expenditure (adaptive thermogenesis) has impor-
tant implications for obesity.
This study focuses on the molecular regulation of gene ex-
pression involved in lipid and energy homeostasis in skeletal
muscle cells by orphan nuclear receptors. We hypothesize that
Nur77 (NR4A1) is involved in mediating -AR signaling and
that skeletal muscle is a critical target tissue in the regulation
of energy expenditure.
Our investigation utilizes small interfering RNA (siRNA)-
mediated knock-out of Nur77 in skeletal muscle cells to under-
stand the regulatory role of a -AR agonist-induced nuclear
hormone receptor in this major mass peripheral tissue. 30–60
min -AR agonist treatment of muscle cells strikingly activated
(100-fold) the expression of the mRNA encoding Nur77. In
contrast, the expression of the other nuclear receptors was not
induced. Furthermore, the study demonstrates that Nur77 is
necessary for the expression of a subgroup of genes involved in
energy balance and expenditure, including AMPK3 and
UCP3. This is consistent with the observation that this orphan
nuclear receptor is hypersensitive to adrenergic stimulation.
MATERIALS AND METHODS
Cell Culture—Mouse myogenic C2C12 cells were cultured in growth
medium (Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated Serum Supreme (BioWhittaker, Edward Keller Pty
Ltd., Hallam, Victoria, Australia)) in 6% CO2. Myoblasts were differen-
tiated into post-mitotic multinucleated myotubes by 5 days of serum
withdrawal (i.e. cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 2% horse serum). Cells were harvested at the indicated
time points, usually 120 h (5 days) after mitogen withdrawal, unless
indicated differently. African green monkey kidney COS-1 cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal calf serum. For the -adrenergic agonist experi-
ments, myotubes were treated with 100 nM isoprenaline hydrochloride
(Calbiochem) or the vehicle control, ethanol, for the indicated time
intervals.
Transient Transfections—Each well of a 24-well plate of COS-1 cells
(60% confluence) was transfected with a total of0.6 g of DNA using
the liposome-mediated transfection procedure as described previously
(13). Cells were transfected using a DOTAP (N-[1-(2,3-dioleoyloxy)pro-
pyl]-N,N,N-trimethylammoniummethyl sulfate andMetafectene (Bion-
tex Laboratories GmbH, Munich, Germany) liposome mixture in 1
HEPES-buffered saline (42 mM HEPES, 275 mM NaCl, 10 mM KCl, 0.4
mM Na2HPO4, 11 mM dextrose (pH 7.1)). The DNA/DOTAP/Metafectene
mixture was added to the cells in 0.6 ml of Dulbecco’s modified Eagle’s
medium supplemented with 5% fetal calf serum. 16 h later the culture
medium was changed, and after a further 24 h the cells were harvested
for the assay of luciferase activity. Values are expressed as relative light
units  S.D. and were derived from a minimum of two independent
experiments composed of six replicates.
C2C12 Stable Transfection—Myogenic C2C12 cells cultured in
growth medium were transfected with pSilencer 2.1-siNur77(DE) by
the liposome-mediated procedure. The cells were then grown for an-
other 24 h to allow cell recovery and neomycin resistance expression
before G418 selection. After 10–14 days of selection with 500 g/ml
G418 (Invitrogen) in culture medium, the polyclonal pool (50 G418-
resistant colonies) of stable transfectants were cultured and maintained
on 50 or 250 g/ml G418 medium.
RNA Extraction and cDNA Synthesis—Total RNA was extracted
from C2C12 cells and tibialis cranialis muscles (after grinding and
homogenization of muscle tissue) using TRI-Reagent (Sigma-Aldrich)
according to manufacturer’s protocol. This was followed by DNase treat-
ment with 2 units of Turbo DNase (Ambion, Austin, TX) for 1 h followed
by heating to 75 °C for 10 min to inactivate the DNase. RNA for
quantitative real time PCR was further purified using the RNeasy RNA
extraction kit (Qiagen, Clifton Hill, Victoria, Australia) according to
manufacturer’s instructions. RNA was quantitated using UV spectro-
photometry, and complementary DNA was synthesized from 3 g of
total RNA using an oligo(dT)18 primer and Superscript III reverse
transcriptase (Invitrogen) according to the manufacturer’s instructions.
Quantitative Real Time (Q-RT)-PCR—Target cDNA levels were an-
alyzed by Q-RT-PCR in 25-l reactions containing either 1 SYBR
green (ABI, Warrington, UK) or Taqman PCR master mix (I,
Branchburg, NJ), 200 nM each forward and reverse primers or 1
Assay-on-Demand Taqman primers (ABI, Foster City, CA), and the
equivalent of 0.3 l of cDNA. Using an ABI Prism 7000 sequence
detection system, PCR was conducted over 45 cycles of 95 °C for 15 s
and 60 °C for 1 min preceded by an initial 95 °C for 10 min to activate
the Amplitaq Gold DNA polymerase. The relative level of expression or
fold change and associated errors were calculated using the guidelines
described by Bookout and Mangelsdorf (19) on the Nuclear Receptor
Signaling Atlas website (NURSA) (www.nursa.org/index.cfm) in accord
with the accepted Q-PCR standards for National Institutes of Health-
supported NURSA research.
Primers—Primers used for Q-RT-PCR analysis of the mRNA popu-
lations have been described in detail (13), with the exception of primers
designed for the detection of Nur77 using SYBR green (Nur77-F, TG-
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Assay-on-demand primer/probe sets for Nur77, AMPK1, and AMPK3
(Applied Biosystems) were also used for Taqman real time PCR.
Plasmids—POMC-tkLUC, pSG5-Nur77, and pSG5 have been de-
scribed previously (20, 21). The pairs of oligonucleotides used for
cloning the Nur77 siRNA targets into the pSilencer 2.1 and 3.1 vector
were as follows: AB region, GATCCCGCTTCCAGCCGTCCCAGCTTT-
TCAAGAGAAAGCTGGGACGGCTGGAAGTTTTTTGGAAA and AGC-
TTTTCCAAAAAACTTCCAGCCGTCCCAGCTTTCTCTTGAAAAGCT-
GGGACGGCTGGAAGCGG; DE region, GATCCCGTCCCTGGCTTCA-
TTGAGCTTTCAAGAGAAGCTCAATGAAGCCAGGGATTTTTTG-
GAAA and AGCTTTTCCAAAAAATCCCTGGCTTCATTGAGCTTCTC-
TTGAAAGCTCAATGAAGCCAGGGACGG. These pairs of oligonucleo-
tides were annealed and cloned into both the pSilencer 2.1 neo and
pSilencer 3.1 neo expression vectors (Ambion, Austin, TX) as per the
manufacturer’s protocol.
In Vivo Electrotransfer into Mice—Plasmid vectors were propagated
in ampicillin-selective media. DNA was extracted, purified using endo-
toxin-free maxi-prep kits (Qiagen Pty Ltd., Doncaster, Victoria, Austra-
lia), and re-suspended in sterile 0.9% saline. Anesthesia was induced in
mice using 5% halothane in oxygen and maintained with 1–2% halo-
thane in oxygen with administration of 5 mg/kg ketoprofen to provide
post-operative analgesia. The hindlimbs of mice were shaved and pre-
pared with a chlorhexidine-ethanol solution, and one tibialis cranialis
muscle was injected in oblique fashion transcutaneously along their
length with 30 l of saline containing 0.5 mg/ml of each vector (pEGFP
and pSilencer 2.1-siNur77(DE)) using a 29-gauge needle. The injection
was immediately followed by the application of a pair of caliper elec-
trodes across the injected leg connected to an ECM-830 electroporator
device (BTX, Holliston, MA). Eight 20-ms pulses of 200 V/cm at a
frequency of 1 Hz were administered as described previously (22). The
other tibialis cranialis muscle was injected in the same fashion with the
appropriate control vectors (pEGFP and pSilencer 2.1 negative) and
electroporated using the same procedure. After recovery, animals were
monitored daily for body weight and general condition. No adverse
effects on the animals were noted during the experiment. One week
after electrotransfer mice were killed, and the tibialis cranialis muscles
were collected and immediately frozen in liquid nitrogen and stored at
70 °C for subsequent analysis.
Western Blotting—Cell lysates normalized for protein concentration
and resolved on SDS-PAGE gels were transferred to polyvinylidene
difluoride or nitrocellulose membranes using semidry transfer. The
molecular mass of resolved proteins was determined by comparison
with Precision Plus markers (Bio-Rad). The membranes were probed
with anti-CPT1-m (CPT1, muscle) polyclonal antibody (Alpha Diagnos-
tic International, Inc., San Antonio, TX), anti-GLUT4 polyclonal anti-
body (a gift of Prof. David James, Garvan Institute of Medical Re-
search), and anti-CAV3 monoclonal antibody (BD Transduction
Laboratories, San Jose, CA) followed by appropriate horseradish per-
oxidase-conjugated secondary antibodies (Zymed Laboratories Inc., San
Francisco, CA). The horseradish peroxidase conjugate was detected
using enhanced chemiluminescence (SuperSignal West Pico Chemilu-
minescent substrate, Pierce), and immunoreactivity was visualized by
autoradiography.
Lipolysis Assay—Triglyceride hydrolysis (lipolysis) was assessed in
C2C12 cells and the C2C12:siNur77 cells using the adipolysis assay kit
(Chemicon Australia Pty Ltd., Boronia, Victoria, Australia) as per the
manufacturer’s instructions. Briefly, C2C12 cells and C2C12-siNur77
cells were differentiated for 5 days, the culture media was removed, and
the monolayer was washed twice with wash solution (Hanks’ balanced
salt solution). 250 l of incubation solution (Hanks’ balanced salt solu-
tion  2% bovine serum albumin) was added to the wells in triplicate,
and cells were incubated for 1, 3, and 6 h. At each time point the
incubation solution was removed and stored at 20 °C until analyzed.
To measure lipolysis, 200 l of free glycerol assay reagent was added to
25 l of culture supernatants and glycerol standards and incubated for
15 min, and the absorbance was read at 540 nm. A standard curve
constructed from the glycerol standards was used to calculate the
concentration of glycerol in the culture supernatants.
RESULTS
Nur77 mRNA Is Expressed in Skeletal Muscle Cells and
Induced during Myogenesis—To elucidate the functional role of
Nur77 in skeletal muscle, we initially investigated the expres-
sion of Nur77 mRNA relative to GAPDH in the mouse C2C12
myoblast cell line. Proliferating C2C12 myoblasts can be in-
duced to biochemically and morphologically differentiate into
FIG. 1.Nur77 mRNA is expressed and induced during myogen-
esis in skeletal muscle cells. A, schematic illustration of the cell
culture model. Proliferating myoblasts were differentiated into post-
mitotic multinucleated myotubes by 5 days of serum withdrawal. B–K,
Q-RT-PCR analysis of mRNA expression during skeletal myogenesis.
RNA extracted from C2C12 PMB and MT5 was reverse-transcribed to
cDNA and analyzed by Q-RT-PCR for each target gene. Results were
normalized to GAPDH and presented as number of target transcripts
per GAPDH transcript S.D. B, Nur77 mRNA levels; C, myogenin
mRNA levels; D, troponin I type 1 (slow) (TNNI1) mRNA levels; E,
troponin I type 2 (fast) TNNI2 mRNA levels; F, UCP3 mRNA levels; G,
LPL mRNA levels; H, GLUT4 mRNA levels; I, fatty acid translocase
(FAT)/CD36 mRNA levels; J, AMPK3 mRNA levels; K, CAV3 mRNA
levels.
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post-mitotic multinucleated myotubes by serum withdrawal in
culture over a 48–96-h period (Fig. 1A).
We utilized the ABI Taqman Nur77 primer set and also used
the GenBankTM sequences of Nur77 to design specific primers
for the SYBR green mediated amplification of mouse Nur77 by
quantitative real time PCR using total RNA isolated from
proliferating and differentiated C2C12 cells. Total RNA was
isolated from proliferating myoblasts and post-mitotic myo-
tubes after 5 days (MT5) of serum withdrawal and converted to
cDNA, and the expression levels of various genes was then
examined by real time PCR.
We observed that Nur77 is weakly expressed in proliferating
myoblasts; however, the transcript is induced 4 fold relative
to GAPDH mRNA as the cells exit the cell cycle and fuse to
form differentiated multinucleated myotubes that have ac-
quired a muscle-specific phenotype (Fig. 1B). Concomitant with
this increase in Nur77 mRNA was the striking induction of the
slow (type I, TNNI1) and fast (type II, TNNI2) isoforms of the
contractile protein, troponin I, relative to GAPDH mRNA (Fig.
1, D and E). Moreover, we observed the significant induction of
myogenin mRNA that encodes the hierarchical bHLH regula-
tor (Fig. 1C). These data confirmed that the cells had termi-
nally differentiated. Furthermore, we observed the induction of
the mRNAs encoding UCP3 (Fig. 1F), LPL (Fig. 1G), the
GLUT4 transporter (Fig. 1H), the fatty acid translocase, CD36
(Fig. 1I), the type II/glycolytic muscle specific AMPK3 (Fig.
1J), and caveolin 3 (CAV3, Fig. 1K). These are examples of
mRNAs encoding proteins involved in the regulation of energy
expenditure and lipid and carbohydrate metabolism (as de-
scribed in Table I). In summary, these data demonstrate that
the mRNA transcript encoding Nur77 was expressed in C2C12
cells in a differentiation-dependent manner, concomitant with
the acquisition of a contractile and metabolic phenotype.
-Adrenergic Agonist Treatment Transiently Induces Nur77
mRNA Expression in Skeletal Muscle Cells—We utilized the
C2C12 cell culture model to examine whether regulatory cross-
talk occurred between the -adrenergic and nuclear hormone
receptor signaling pathways in skeletal muscle. There has been
a single report describing the induction of Nur77 by adrenergic
agonists in muscle (11), and a second manuscript reported that
epinephrine induced Nur77 in the brain (23); however, these
single observations have not been reproduced in the literature.
Therefore, to investigate and substantiate these conclusions,
we treated differentiated post-mitotic skeletal muscle myo-
tubes with the -adrenergic agonist, isoprenaline (and the ve-
hicle, ethanol) for 30, 45, 60, 120, and 240 min and subse-
quently isolated total RNA. Q-RT-PCR was utilized to examine
the expression of mRNAs encoding Nur77 and a number of
other nuclear hormone receptors that regulate lipid homeosta-
sis. Interestingly, we observed that the mRNA encoding Nur77
was dramatically induced (100-fold) after 30–60 min of incu-
bation with isoprenaline (Fig. 2). Activation of expression was
transient and declined after 60 min of treatment. There was a
slight induction of Nur77 with ethanol alone, a response that
has been noted in another report (24), and this is not surprising
FIG. 2. -Adrenergic agonist (isoprenaline) treatment tran-
siently induces Nur77 expression in skeletal muscle cells. C2C12
MT5 cells were treated with vehicle (ethanol) or isoprenaline for 30, 45,
60, 180, and 240 min. Levels of Nur77 mRNA were quantitated by
Q-RT-PCR. Expression was normalized and presented as the number of
target transcripts per 18 S transcript  S.D.
TABLE I
Key target genes in this study
ABCA1 and ABCG8 ATP binding cassette. Transporters that transfer cholesterol to the high density lipoprotein acceptors,
i.e. reverse cholesterol efflux.
ACS4 Acyl-CoA synthetase 4. Enhances the uptake of fatty acids by catalyzing their activation to acyl-CoA
esters for subsequent use in catabolic fatty acid oxidation pathways.
ADRP/adipophilin Adipocyte differentiation-related protein. Involved in lipid storage.
AdipoR1 and -R2 Adiponectin Receptors 1 and 2. Cell surface membrane receptors for adiponectin that regulate glucose
uptake and fatty acid oxidation (38).
AMPK 5	-AMP-activated protein kinase. A fuel-sensing enzyme that responds to cellular stress by regulating
carbohydrate and fat metabolism (60).
ApoE Apolipoprotein E. Facilitates cholesterol and lipid efflux.
CAV3 Caveolin 3. Muscle-specific caveolin involved in membrane protein anchoring, caveolae, t-tubules
formation, and lipid trafficking.
CPT-1 Carnitine palmitoyl transferase 1. Transfers the long chain fatty acyl group from coenzyme A to
carnitine, the initial reaction of mitochondrial import of long chain fatty acids and their subsequent
oxidation.
FAS Fatty acid synthase. Involved in de novo fatty acid production.
FAT/fatty acid translocase
and FABP3
Fatty acid translocase, and fatty acid binding protein. Facilitate uptake of long chain fatty acids
(LCFAs) and low density lipoproteins.
GLUT4 and -5 Glucose transporters. GLUT4 facilitates glucose uptake in response to insulin stimulation. GLUT5
catalyzes uptake of fructose.
Glycogenin/GYG1 Initiates the synthesis of glycogen, the principal storage form of glucose in skeletal muscle.
LPL Lipoprotein lipase. Hydrolysis of lipoprotein triglycerides into free fatty acids and responsible for the
uptake of free fatty acids.
PDK2 and -4 Pyruvate dehydrogenase kinases. Inhibits the pyruvate dehydrogenase complex, thereby controlling
glucose oxidation and maintaining pyruvate for gluconeogenesis.
SCD1 and -2 Stearoyl CoA desaturase 1 and 2. Enzymes associated with adiposity, i.e. storage and esterification of
cholesterol and responsible for the cis saturation of stearoyl and palmitoyl-CoA, converting them to
oleate and palmitoleate, which are the monounsaturated fatty acids of triglycerides.
SREBP-1c Sterol regulatory element binding protein 1c. The hierarchical transcriptional activator of lipogenesis.
UCP1, -2, and -3 Uncoupling proteins. Mitochondrial proteins that uncouple metabolic fuel oxidation from ATP-synthesis,
regulating energy expenditure.
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given that Nur77 has been implicated as a stress-response gene
(25). Furthermore, we examined the expression of many other
nuclear hormone receptors that have been demonstrated to
regulate lipid and carbohydrate metabolism, including ERR-1,
PPAR, -/, and -, LXR and -, Rev-erb, RVR, ROR, and
COUP-TFI and II. In contrast to the striking induction of
Nur77, the expression of the mRNAs encoding the NRs above
did not respond to -adrenergic agonist treatment (Table II).
In summary, these data clearly demonstrate that -adrener-
gic agonists selectively and dramatically activated the mRNA
encoding Nur77 (and not other nuclear receptors). This sug-
gests that -adrenergic agonists and Nur77 may have a unique
regulatory footprint in skeletal muscle cells and demonstrates
cross-talk between the -adrenergic and an orphan nuclear
hormone receptor pathway.
Nur77-siRNA Expression Attenuates Nur77-mediated Gene
Expression and Represses Endogenous Levels of Nur77
mRNA—To understand the biological role of Nur77 in skeletal
muscle lipid and energy homeostasis and to identify the meta-
bolic target genes of this orphan receptor in muscle cells, we
proceeded to examine the effect of ablation. This would provide
a tool for elucidating the consequences of -AR-mediated in-
duction of Nur77. Furthermore, the analysis of the C2C12-
siNur77 cell line would ascertain the extent of cross-talk be-
tween the -adrenergic and Nur77-signaling pathways in the
context of target genes and metabolic pathways.
We utilized RNA interference to achieve targeted silencing of
Nur77 using double-stranded siRNA expression as the trigger-
ing agent. Two siRNA target sequences were chosen using the
siRNA target finder on the Ambion web site (www.ambion.com/
techlib/misc/siRNA_finder.html). The selected siRNAs (Fig.
3A) were cloned into the Silencer 2.1 and 3.1 plasmid expres-
sion vectors, driven, respectively, by the U6 and H1 RNA po-
lymerase III promoters. The efficacy of the cloned siRNAs and
their ability to attenuate trans-activation of the native Nur77-
dependent heterologous reporter gene (Fig. 3B) in the presence
of exogenous and overexpressed Nur77 was analyzed. This
demonstrated that the Silencer 2.1 plasmid driving the siRNA
targeting the C-terminal DE region (encoding the putative
ligand binding domain of Nur77) most successfully attenuated
Nur77-dependent gene expression.
We stably transfected C2C12 cells with the Silencer 2.1-
siNur77(DE) vector and isolated a polyclonal pool of G418-
resistant colonies (comprised of 50 G418 resistant colonies
and, henceforth, denoted as C2C12-siNur77). Q-RT-PCR dem-
onstrated the C2C12-siNur77 cells expressed reduced levels
(10-fold) of the Nur77 mRNA transcript relative to the native
C2C12 cells (Fig. 3C). In conclusion, the C2C12-siNur77 cell
line displayed attenuated Nur77 mRNA expression.
Exogenous Nur77-siRNA Represses the Expression of the
mRNAs Encoding Genes That Regulate Lipid and Energy Ho-
meostasis—The C2C12 in vitro cell culture system has been
extensively used to investigate the regulation of lipid homeo-
stasis (12, 13, 17, 26–30). Moreover, the physiological valida-
tion of the cell culture model with respect to the control of lipid
metabolism by LXR and PPARs in the mouse (14, 17, 18, 31, 32)
corroborates the utility of this model system.
Hence, we proceeded to examine the effect of attenuating
Nur77 mRNA expression on the expression of genes involved in
lipid and energy homeostasis (see Table I). We compared ex-
pression in the siNur77-expressing stable cell line relative to
the wild type C2C12 cell line. Specifically, both cell lines were
induced to differentiate into post-mitotic multinucleated myo-
tubes by mitogen withdrawal in culture over a 5-day period and
isolated total RNA from the native and siNur77-expressing cell
line for Q-RT-PCR analysis.
Initially, we examined the expression of markers indicative
of differentiation to ascertain whether the siNur77 cell line
retained the potential to morphologically and biochemically
differentiate. Over a 5-day period the C2C12-siNur77 cell line
TABLE II
Relative expression of nuclear hormone receptors after vehicle and isoprenaline treatment, presented as the number of
target transcripts per 18 S transcript
Time




ERR-1 94.674  0.504 137.654  0.180 163.321  1.056 121.789  1.205 119.835  0.268
PPAR 2.025  0.012 2.735  0.032 4.964  0.017 2.171  0.024 1.238  0.007
PPAR/ 120.668  0.975 176.261  0.900 211.069  1.238 203.408  0.982 123.917  0.034
PPAR 15.400  0.062 18.230  0.042 30.659  0.086 21.679  0.025 16.129  0.128
LXR 3.895  0.004 4.828  0.001 7.336  0.025 3.486  0.014 3.283  0.005
LXR 455.583  2.470 673.205  2.721 866.007  3.611 538.040  1.200 562.185  6.576
ROR 1.432  0.015 1.834  0.006 6.154  0.019 5.296  0.021 0.850  0.003
Rev-erb 68.194  0.118 79.428  0.142 94.020  0.539 51.562  0.235 50.152  0.570
RVR (Rev-erb) 7.020  0.022 9.612  0.026 27.824  0.047 32.784  0.087 4.107  0.021
COUP-TFI 316.977  2.650 427.042  1.443 632.491  3.361 437.024  0.574 160.330  0.626
COUP-TFII 170.651  1.242 264.704  0.739 455.583  1.222 259.856  0.997 114.423  0.211
Vehicle (ethanol)-treated
C2C12 myotubesb
ERR-1 94.674  0.504 191.107  0.260 160.330  0.893 202.471  0.321 130.530  0.277
PPAR 2.025  0.012 4.262  0.010 4.392  0.019 3.000  0.033 2.878  0.020
PPAR/ 120.668  0.975 213.521  1.257 204.823  0.260 262.269  1.322 120.112  0.324
PPAR 15.400  0.062 26.567  0.095 28.212  0.111 26.384  0.104 42.466  3.091
LXR 3.895  0.004 6.416  0.061 7.037  0.027 7.053  0.009 3.626  0.007
LXR 455.583  2.470 956.465  3.389 766.195  6.138 876.070  1.006 612.360  2.709
ROR 1.432  0.015 3.758  0.021 4.292  0.020 2.232  0.018 1.872  0.022
Rev-erb 68.194  0.118 115.486  0.112 101.939  0.267 96.887  0.064 64.218  0.363
RVR (Rev-erb) 7.020  0.022 14.469  0.068 13.345  0.045 10.616  0.017 8.121  0.015
COUP-TFI 316.977  2.650 682.603  1.155 623.784  4.209 403.074  0.677 238.564  2.291
COUP-TFII 170.651  1.242 415.365  1.099y 376.952  1.937 246.977  0.263 239.116  0.665
a Untreated control sample.
b C2C12 cells were grown to confluence, differentiated for 72 h by serum withdrawal, then treated for the specified period. Values are expressed
as mean  S.D. of the expression relative to 18 S (2(
Ct)  106).
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retained the potential to morphologically differentiate. More-
over, the induction and activation of myogenin (Fig. 4A), tro-
ponin I slow (Fig. 4B, TNNI1), and troponin I fast (Fig. 4C,
TNNI2) mRNA expression after serum withdrawal demon-
strated that the cell line biochemically differentiated. Further-
more, we examined the relative expression of myogenin and
TNNI1 and -2 in wild type C2C12 versus C2C12-siNur77 myo-
tubes after 5 days of serum withdrawal. We observed that
myogenin mRNA expression (Fig. 4D) was increased 2-fold,
whereas TNNI1 (Fig. 4E) and TNNI2 (Fig. 4F) mRNA expres-
sion were down-regulated 3-fold.
For the sake of brevity we will only show the graphical data
for a number of genes; the complete list of genes examined and
their relative expression are presented in Table III. In the
context of lipid and fatty acid absorption we observed signifi-
cant (8-fold) repression of the mRNA encoding fatty acid
translocase (FAT/CD36, Fig. 5A) relative to the changes ob-
served in the biochemical markers of differentiation. Moreover,
the noteworthy repression of CD36 was highlighted by the
minor changes (2.5-fold) observed for fatty acid-binding pro-
tein 3 (FABP-3) and 4 (FABP-4) in the siNur77-expressing cell
line, respectively (see Table III), similar to the minor changes
observed in the biochemical markers of differentiation. These
negligible alterations in the siNur77-expressing cell line corre-
lated with the subtle up and down variations observed in the
biochemical markers of differentiation, in contrast to the dra-
matic repression of CD36 mRNA expression.
The expression of the mRNA encoding the glucose trans-
porter, GLUT4, was repressed 10-fold (Fig. 5B) in the
siNur77-expressing cell line. In contrast, the expression of the
mRNA encoding the fructose transporter, GLUT5, was un-
changed by Nur77 attenuation (Fig. 5C, Table III).
In the context of the regulation of energy expenditure and
energy balance, we examined the expression of several genes
(see Tables I and III). The expression of a small subgroup of
genes emerged as being clearly dependent on Nur77 expres-
sion. For example, the mRNAs encoding UCP3 and AMPK3
(preferentially expressed in glycolytic fast muscle fibers) were
significantly repressed (6–20-fold; Fig. 5, D and H) in the
siNur77-expressing cell line relative to the 2-fold changes
observed in the markers of differentiation (Fig. 4, D–F, Table
III). Consistent with the effects on this subgroup of genes, we
observed that adiponectin receptor 2 (Fig. 5F) (but not adi-
ponectin receptor 1; Fig. 5G) was repressed 4-fold). This re-
ceptor for the anti-diabetic adipokine Acrp30/adiponectin has
been reported to activate AMPK and fatty acid oxidation.
Interestingly, the mRNA encoding the hierarchical regulator
of lipogenesis, sterol regulatory element binding protein-1c
(SREBP-1c), was increased 4-fold; this is consistent with
abrogation of AMPK3 mRNA expression, which in animals
leads to excessive triglyceride accumulation (33). Surprisingly,
the lipogenic downstream target genes including stearoyl-CoA
desaturase 1 and 2 and fatty acid synthase (see Table III) were
not affected in the siNur77-expressing cell line. The expression
of the transcripts encoding LPL, muscle type carnitine palmi-
toyltransferase-1, medium chain acyl-CoA dehydrogenase, and
acyl-CoA synthetase-4 (ACS4), which are involved in lipid ca-
tabolism and preferential fuel utilization, were not affected in
the siNur77-expressing cell line (see Tables I and III).
Additionally, we did not observe any changes in the expres-
sion of mRNAs encoding ATP binding cassette A1, ATP binding
cassette A8/G1), apolipoprotein E, adipophilin, and glycoge-
nin-1 (see Tables I and III), involved in cholesterol homeostasis
and lipid and glucose storage in the cells expressing the
siNur77. However, we observed that the mRNA encoding
caveolin-3, which has been implicated in lipid transport and
storage (34, 35), was significantly suppressed (13-fold, Fig.
5J) in the siNur77 cell line.
Furthermore, we examined the expression of many other
nuclear hormone receptors that have been demonstrated to
regulate lipid and carbohydrate metabolism, including ERR-1,
PPAR, -/, and -, LXR and -, Rev-erb, RVR (Rev-erb),
ROR, and COUP-TFI and -II and found that siNur77 expres-
sion did not affect the expression of the mRNAs encoding the
other orphan NRs.
We utilized Western analysis to confirm that some of the
critical changes in mRNA expression translated to changes in
protein expression. For example, we examined the expression
of caveolin 3 and GLUT4 expression in the native C2C12 and
the siNur77-expressing cells because the mRNAs encoding
these proteins were significantly repressed in the C2C12:
siNur77 cell line. As a control we also examined the protein
expression of CPT-1 because the mRNA encoding this enzyme
was not affected by attenuation of Nur77 expression. Consist-
ent with the mRNA expression profiling, we observed signifi-
cant suppression of caveolin 3 and GLUT4 protein expression
in the siNur77-expressing cells (Fig. 6, A and B), whereas
CPT-1 protein expression remained unchanged (Fig. 6C).
FIG. 3. Nur77 siRNA attenuates Nur77-dependent trans-acti-
vation and represses the endogenous levels of Nur77 mRNA
expression. A, diagrammatic representation of Nur77 depicting the
location of the N- and C-terminal siRNAs. B, pSG5-Nur77 and either
pSilencer 2.1 negative or pSilencer 2.1-Nur77(DE) were co-transfected
with POMCx5-TKLuc into COS-1 cells. Mean luciferase activity is
expressed as relative light units (RLU)  S.D. (n  6). C, Q-RT-PCR
analyses of Nur77 mRNA levels in native C2C12 and C2C12-siNur77
myotubes, with expression normalized and presented as the number of
target transcripts per GAPDH transcript  S.D. aa, amino acid.
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In summary, the expression of a subgroup of genes involved
in glucose absorption, lipid homeostasis, and the regulation of
energy balance including GLUT4, CD36, CAV3, AMPK3, adi-
ponectin receptor 2, and UCP3 emerged as clearly dependent
on Nur77 expression. The Nur77-specific dependence of this
subgroup of metabolic genes was underscored by the observa-
tion that related genes, for example GLUT5, UCP2, AMPK1,
and adiponectin receptor 1, were refractory to a reduction in
Nur77 expression.
Lipolysis Is Reduced in the siNur77-expressing Cells—Our
study demonstrated that that a subgroup of genes that include
adiponectin receptor 2, UCP3, and AMPK3 are repressed in
the C2C12:siNur77 cell line. Studies in a variety of animal
models suggest that suppression of these genes would lead to a
reduction in fatty acid oxidation, reduced lipid utilization, and
lipolysis. For example, muscle-specific overexpression of UCP3
leads to preferential lipid utilization (36, 37), adiponectin re-
ceptor 2 activation leads to increased -oxidation (38), and
AMPK3 null mice exhibit triglyceride accumulation (33).
To test this hypothesis in our cell culture system we exam-
ined lipolysis (triglyceride hydrolysis) in the native C2C12 cells
and in the siNur77-expressing cells. Lipolysis/triglyceride
breakdown was measured by examining glycerol release into
the cell culture supernatant after 1-, 3-, and 6-h incubations.
We utilized the Chemicon adipolysis kit to measure lipolysis
and observed that glycerol release was significantly reduced
from the C2:siNur77 cell line relative to the native C2C12 cell
line (Fig. 7). This demonstrates that attenuation of Nur77
expression results in reduced lipolysis in skeletal muscle cells.
Expression of Nur77 siRNA in Mouse Tibialis Muscle Leads
to Repression of UCP3 mRNA Expression—To examine
whether the effects and changes observed in the skeletal mus-
cle cell culture model were reflected in an in vivo animal model,
we injected and electroporated mouse tibialis muscle with the
Nur77 siRNA expression vector. Specifically, the right hind-
limb tibialis cranialis muscle of three mice was injected in
oblique fashion transcutaneously with the pSilencer 2.1
siNur77 expression using a 29-gauge needle followed by elec-
trotransfer as described (22). The left hindlimb tibialis crani-
alis muscle was injected with the pSilencer 2.1 control vector
and electroporated using the same procedure. One week after
electrotransfer mice were sacrificed, the tibialis cranialis mus-
cles were collected, and RNA was harvested for subsequent
analysis. Expression of pSilencer 2.1-siNur77 produced an 2-
fold repression in Nur77 mRNA expression in the right tibialis
cranialis muscle relative to the left muscle injected with the
control silencer vector only (Fig. 8A). In agreement with the cell
culture model, we observed a repression in UCP3 mRNA ex-
pression (Fig. 8B). This data confirmed that a key change
reported in the cell culture model, viz. a down-regulation of
UCP3 expression, was confirmed in mouse skeletal muscle.
DISCUSSION
Genetic, molecular, and biochemical studies have clearly
demonstrated that -adrenergic agonists and -ARs are in-
volved in the regulation of cold- and diet-induced thermogene-
sis and induce increases in energy expenditure (3–5). However,
the target tissues, UCP1-independent mechanisms, and molec-
ular pathways involved in diet-induced thermogenesis have not
been resolved and remain a controversial area. One favorable
respectively, in the C2C12-siNur77 cell line. D, E, and F, Q-RT-PCR
analyses of myogenin and troponin I type I (slow) and II (fast) mRNA
levels, respectively, in the native C2C12 and the C2C12-siNur77 cell
line. Expression was normalized and presented as number of target
transcripts per GAPDH transcriptS.D. PMB, proliferating myoblasts;
MT5, post-mitotic myotubes after 5 days.
FIG. 4. The C2C12-siNur77 cell line acquires biochemical
markers of skeletal muscle. A, B, and C, Q-RT-PCR analyses of
myogenin and troponin I type I (slow) and II (fast) mRNA levels,
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hypothesis suggests that a putative target tissue(s) of the sym-
pathetic nervous system (liver, skeletal muscle, and/or white
adipose) mediates the diet and -adrenergic-induced increases
in energy expenditure and thermogenesis (3). The observation
that Nur77/NR4A1 is dramatically and transiently induced in
skeletal muscle cells by isoprenaline, a -adrenergic agonist,
prompted us to examine the metabolic role of this receptor in
skeletal muscle cells.
The expression of Nur77 in skeletal muscle, a peripheral
lean tissue that has a significant role in energy expenditure,
glucose disposal, and -oxidation, led us to investigate the role
of Nur77 in skeletal muscle cells with respect to the expression
of genes involved in metabolism. Recent publications utilizing
the C2C12 cell culture system suggest it is an ideal paradigm to
investigate the regulation of lipid homeostasis in skeletal mus-
cle (12, 13, 17, 27–30). Furthermore, our initial observation
that isoprenaline treatment elicited a dramatic response in
Nur77 mRNA expression coupled to the specific and selective
induction of this orphan nuclear receptor (in contrast to other
nuclear receptors involved in metabolism and metabolic dis-
ease) underscored the distinctive cross-talk between the adre-
nergic and orphan nuclear receptor pathways in skeletal mus-
cle cells (Fig. 9). Our study demonstrates that a subgroup of
genes (that includes adiponectin receptor 2, UCP3, AMPK3,
CAV3, CD36, and GLUT4) involved in the regulation of energy
balance and expenditure are dependent on the expression of
Nur77. The Nur77-specific dependence of this subgroup of met-
abolic genes was highlighted by the observation that related
genes, for example GLUT5, UCP-2, AMPK1, and adiponectin
receptor 1, were refractory to a reduction in Nur77 expression.
TABLE III
Relative mRNA expression and -fold change for genes involved in metabolism from native C2C12 and C2C12-siNur77 cells
MCAD, medium chain acyl-CoA dehydrogenase; ADRP, adipocyte differentiation-related protein; FAS, fatty acid synthase; FABP, fatty
acid-binding protein; PDK, pyruvate dehydrogenase kinase; SCD, stearoyl-CoA desaturase; ACS4, acyl-CoA synthetase 4; ABC, ATP binding
cassette; PGC-1, peroxisome proliferator-activated receptor gamma, coactivator 1; GYG1, glycogenin.
Gene Relative expression C2C12a Relative expression C2C12-siNur77a -Fold changeb
Nuclear receptors
Nur77 75.12  9.87 7.07  1.36 210.63  2.47
ERR-1 21.62  2.76 15.75  1.70 21.37  0.23
PPAR 0.58  0.19 0.37  0.13 21.56  0.76
RVR (Rev-erb) 5.40  1.33 8.01  2.16 11.48  0.54
Rev-erb 8.21  1.42 7.22  2.18 21.14  0.40
COUP-TFI 65.54  5.81 130.18  10.03 11.99  0.23
COUP-TFII 93.55  7.77 164.40  19.81 11.76  0.26
PPAR/ 44.66  3.38 106.23  7.94 12.38  0.25
PPAR 27.24  1.74 70.25  2.59 12.58  0.19
Fatty acid and lipid absorption
CD36 81.25  10.72 9.99  1.20 28.13  1.45
FABP-3 275.84  0.40 98.89  0.94 22.79  0.62
FABP-4 0.33  0.09 0.31  0.07 21.07  0.38
Sugar uptake
GLUT1 22.08  6.18 35.37  7.22 11.60  0.55
GLUT4 0.79  0.098 0.07  0.004 210.83  1.47
GLUT5 0.25  0.030 0.19  0.026 21.33  0.25
Lipid catabolism
LPL 202.40  7.89 237.93  27.37 11.18  0.14
CPT-1 3.38  0.28 3.25  0.15 21.04  0.10
ACS4 55.50  7.33 90.78  12.48 11.64  0.31
AdipoR1 683.14  24.07 751.89  73.95 11.10  0.11
AdipoR2 0.85  0.09 0.21  0.03 24.03  0.67
PGC-1 6.79  0.98 22.91  0.89 13.37  0.50
PDK-2 127.80  11.84 69.76  15.96 21.83  0.45
PDK-4 25.42  2.04 35.12  4.87 11.38  0.22
MCAD 45.50  6.34 63.31  8.01 11.39  0.26
Energy expenditure
UCP3 0.28  0.06 0.014  0.003 220.49  6.09
UCP2 429.86  43.04 150.23  19.44 22.86  0.47
Energy balance
AMPK1 5.65  0.74 10.79  0.44 11.91  0.26
AMPK1 120.35  12.31 132.61  7.26 11.10  0.13
AMPK3 65.85  7.43 10.99  0.70 25.99  0.78
Lipid efflux and homeostasis
ABCA1 0.45  0.19 1.21  0.11 12.69  1.19
ABCG1 0.21  0.08 0.22  0.07 11.05  0.53
ApoE 108.46  0.487 106.72  0.628 21.02  0.20
CAV1 151.63  5.29 295.64  32.79 11.95  0.23
CAV3 698.30  61.54 52.02  8.09 213.42  2.40
Lipid and glucose storage
ADRP 1063.33  387.40 1524.77  128.29 11.43  0.54
GYG1 124.30  14.07 88.51  9.75 21.40  0.22
Lipogenesis
SREBP-1c 0.67  0.004 3.08  0.041 14.57  1.58
SCD-1 1684.04  303.64 1626.68  144.25 21.04  0.21
SCD-2 521.93  94.66 544.09  55.77 11.04  0.22
FAS 133.22  24.06 177.83  16.52 11.33  0.27
Contractility/myogenic markers
TNNI1 18703.82  2996.83 5763.43  547.03 23.25  0.60
TNNI2 14573.36  2143.64 4480.30  507.29 23.25  0.60
Myogenin 141.47  14.91 290.90  78.90 12.06  0.60
a Relative expression expressed as number of transcripts per GAPDH transcript S.D.
b -Fold change S.D.
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FIG. 5. Expression profiling by Q-RT-PCR of mRNAs involved in metabolism; analyses of the wild type native C2C12 cells and the
C2C12-siNur77 cells. Q-RT-PCR analysis of endogenous mRNA expression encoding enzymes/proteins involved in lipid homeostasis, energy
expenditure, etc. (described in Table I). The results were normalized and presented as the number of target transcripts per GAPDH transcript
S.D. The category in Table I to which these genes belong is indicated. Lipid absorption, fatty acid translocase (CD36/FAT) (A); sugar uptake,
GLUT4 (B) and GLUT5 (C); energy expenditure, UCP2 (D) and UCP3 (E); lipid catabolism, adiponectin receptor 2 (AdipoR2) (F) and AdipoR1 (G);
energy balance, AMPK3 (H) and AMPK1 (I); lipid efflux and storage, CAV3 (J).
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These observations of cross-talk between Nur77 and the adre-
nergic pathways and the identification of this Nur77-depend-
ent subgroup of genes is entirely consistent with the phenotype
of the -AR null/-less mice (5), which develop severe obesity
on a high fat diet due to a deficiency in diet-induced thermo-
genesis and energy balance.
The mice lacking all three known 123-ARs (denoted “-less
mice”) have a reduced metabolic rate and develop mild obesity,
and these mice are unresponsive to cold and -agonist stimu-
lation. Oxygen consumption does not change in response to
physiological cold exposure or pharmacological stimulation,
and as mentioned above, the -less mice develop severe obesity
on a high fat diet. The diet-induced increase in oxygen con-
sumption is conspicuously absent in the -less mice, in contrast
to the 20% increase in oxygen consumption observed in wild
type mice after 5 days (5). Finally, linkage and association
studies have implicated the -adrenergic receptors in the ac-
cumulation of abdominal and visceral fat, which is consistent
with the obesity risk in individuals with -AR mutations, de-
letions, and polymorphisms (39–44).
Unfortunately, the target tissue of sympathetically mediated
diet-induced adaptive thermogenesis remains obscure. Brown
adipose tissue (a sympathetically innervated tissue that ex-
presses UCP1) was thought to be the target tissue for diet-
induced thermogenesis; however, the observation that the
UCP1 / mouse phenotype is compromised for cold-induced
thermogenesis but resistant to diet-induced obesity (6) has
challenged this theory. Undoubtedly, -ARs are required for
diet-induced thermogenesis, and possible explanations involve
UCP-2/3-dependent mechanisms and other sympathetically in-
nervated target tissues, for example skeletal muscle, liver, or
white adipose tissue (3).
In the context of this investigation a single report in the
literature suggested that -adrenergic agonists in cultured
skeletal muscle cells transiently induce Nur77 mRNA expres-
sion (11). This observation was dramatically confirmed in our
current study. However, the role of Nur77 in the regulation of
energy balance and uncoupling in skeletal muscle (or any other
major mass peripheral tissue), potential Nur77 target genes,
and the mechanism of action in this metabolically demanding
major mass lean tissue has remained obscure.
Our investigation has highlighted the unique and selective
cross-talk between the adrenergic and orphan nuclear receptor
pathways in skeletal muscle cells. Our study demonstrated
that a subgroup of genes (including adiponectin receptor 2,
AMPK3, UCP3, CAV3, CD36, and GLUT4) involved in the
regulation of energy homeostasis is demonstrably dependent
on the expression of Nur77 in skeletal muscle cells. Moreover,
in initial animal studies we confirmed that attenuation of
Nur77 expression in mouse tibialis muscle leads to reduced
UCP3 expression. The relationship of this Nur77-dependent
subgroup of genes is consistent with the phenotype of the obese
-AR less null mice. A number of studies have investigated
ectopic and muscle-specific overexpression of UCP3 in trans-
genic mice and in cell culture (45–47). These investigations
have reported (i) increased rates of energy expenditure, (ii)
preferential lipid utilization and lipolysis, (iii) resistance to
high fat diet-induced weight gain and obesity in the context of
FIG. 6. CAV3 and GLUT4 protein levels are reduced and CPT-1 protein levels remain unchanged in C2C12 and C2C12-siNur77
cells. Total protein was extracted from C2C12 and C2C12-siNur77 cells, and 20 g was resolved by SDS-PAGE. Separated proteins were
transferred to polyvinylidene difluoride membranes, and immunoreactive proteins were detected using a monoclonal antibody to CAV3 and
polyclonal GLUT4 and CPT-1 antibodies. CAV3 (A), GLUT4 (B), and CPT-1 (C) are shown as indicated (arrowhead) in each panel together with
the molecular mass of the resolved protein standards (in kDa). Panel D, -tubulin (input control for protein loading). WT, wild type.
FIG. 7. Triglyceride hydrolysis is reduced in the siNur77-ex-
pressing cells. C2C12 cells and C2C12-siNur77 cells were differenti-
ated for 5 days and assessed for triglyceride hydrolysis using a com-
mercial lipolysis assay (Chemicon). Supernatants from cells incubated
for 1, 3, and 6 h were assayed for free glycerol. Results are expressed as
nmol of glycerol released/ml/h (mean  S.D. of individual wells, n  3).
Statistical significance was assessed using Student’s t test. p  0.05 (*),
p  0.01 (**); p  0.001 (***), compared with wild-type C2C12 cells.
FIG. 8. UCP3 mRNA expression is repressed in mouse muscles
transiently expressing Nur77 siRNA. Mouse tibialis cranialis mus-
cles were injected and electroporated with a Nur77 siRNA expression
vector or negative control vector. Muscles were collected 1 week later
and processed for RNA, and the level of Nur77 and UCP3 mRNA
expression was determined by Q-RT-PCR. Values obtained from three
animals were pooled, normalized, and expressed as the number of
target transcripts per 18 S transcript S.D.
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hyperphagic behavior, (iv) lower fasting plasma glucose and
insulin levels, (v) increased glucose tolerance and clearance
rate, and (vi) adaptive thermogenesis. These studies emphasize
the regulatory role of UCP3 in metabolic efficiency/energy ex-
penditure and thermogenesis and in preferential substrate uti-
lization. We hypothesize that the effects of Nur77 agonists on
skeletal muscle, a major mass peripheral tissue, would have
therapeutic utility and protect against diet-induced obesity.
Similarly, we observed a reduction in the expression of the 3
subunit of AMP-activated protein kinase in the siNur77-C2C12
cell line. This AMPK isoform is predominantly expressed in
type II glycolytic muscle (48). Mutation of AMPK3 leads to the
dramatic accumulation of glycogen in type II fast twitch white
fibers, whereas AMPK3 null mice exhibit insulin resistance
and triglyceride accumulation (33). AMPK is a critical protein
kinase that operates as a metabolic stress sensor and regulator
of energy balance, acting to increase fatty acid oxidation and
glucose uptake and inhibit triglyceride biosynthesis (33, 49).
Furthermore, recent data has suggested that the reduction in
adiposity induced by adrenergic agonists involves AMPK acti-
vation in peripheral tissues (50). Our data demonstrating that
the expression of AMPK3 mRNA is dependent on the expres-
sion of a nuclear hormone receptor that is hypersensitive to
-adrenergic stimulation is entirely consistent with the role of
AMPK in the regulation of energy balance and a sensor of
metabolic stress (49). Furthermore, and excitingly, our data
implicate the orphan nuclear receptor Nur77 in the regulation
of energy homeostasis. The coupled suppression of UCP3 and
AMPK3 expression is also consistent with the activation of
UCP3 in type II fibers by the AMPK activator, AICAR (51).
Suppressed expression of UCP3 and AMPK3 mRNA in the
siNur77 cell line is consistent with the attenuated lipolysis
observed in this cell line. This is entirely consistent with many
animal studies that demonstrate muscle-specific overexpres-
sion of UCP3 and/or AMPK3 leads to preferential lipid utili-
zation and increased lipolysis. Correspondingly, attenuation of
UCP3 and/or AMPK3 expression leads to triglyceride accu-
mulation and reduced lipolysis (33, 36, 37).
The elevated expression of SREBP-1c mRNA in the siNur77
cell line without the corresponding increases in downstream
target genes involved in lipogenesis (e.g. fatty acid synthase,
stearoyl-CoA desaturase 1 and 2) is not entirely surprising.
This interesting observation, i.e. that the regulation of
SREBP-1c may be uncoupled from fatty acid metabolism in
skeletal muscle, has been reported in an LXR animal model
study (17). This manuscript reported LXR-mediated activation
of SREBP-1c in liver and skeletal muscle. However, the
mRNAs encoding stearoyl-CoA desaturase-1 and fatty acid syn-
thase were not induced by LXR agonist treatment in muscle (in
contrast to the observations in the livers of treated mice).
We also demonstrated that GLUT4 mRNA and protein ex-
pression was significantly repressed in the C2C12-siNur77 cell
line, which was in accord with the reduction in AMPK3 and
UCP3 mRNA expression. Many studies have shown links be-
tween AMPK, UCP3, and glucose metabolism. For example,
AMP kinase activators failed to induce skeletal muscle glucose
uptake in the AMPK3 knock-out mice (33), overexpression of
GLUT4 increases the expression of UCP3 in skeletal muscle
(52), and muscle-specific overexpression of UCP3 leads to in-
creased glucose tolerance and a lean phenotype despite hy-
perphagia (53).
The lower levels and Nur77-dependent expression of the
mRNA encoding the fatty acid translocase, CD36, also correlate
with the reduction of AMPK3 and UCP3 expression, as the
-oxidation demands in these cells would be reduced. Muscle-
specific overexpression of CD36 ameliorates insulin resistance
and hyperglycemia caused by dominant negative IGF-1 recep-
tor expression. Furthermore, CD36 overexpression normalizes
the fatty acid oxidation defect in these mice (54). Correspond-
ingly, CD36 nonsense mutations lead to insulin resistance and
familial type II diabetes (55), and CD36 polymorphisms have
been linked to increases in free fatty acids and triglycerides
(56). Interestingly, we did not observe significant changes in
the expression of the genes involved in lipid catabolism and
-oxidation (e.g. LPL and CPT-1). However, this is not surpris-
ing as increased or decreased flux of fatty acids through the
oxidation pathway does not necessarily require marked
changes in genes involved in fat catabolism (45).
Finally, we demonstrated that the expression of the caveo-
lin-3 gene and its encoded protein are attenuated dramatically
in the C2C12-siNur77 cell line. Although caveolin-3 has not
been directly linked to lipid regulation, studies of the non-
muscle caveolin family member, caveolin-1, have suggested a
role for caveolins in cholesterol transport to extracellular cho-
lesterol acceptors such as high density lipoprotein (57, 58).
Non-striated muscle caveolins 1 and 2 associate with lipid
droplets in cultured cells and in vivo (35). Moreover, caveolin-1
null mice are resistant to diet-induced obesity (59). The studies
presented here linking Nur77 expression to the regulation of
caveolin-3 mRNA expression, and the Nur77-dependent nature
of the other identified genes involved in the regulation of en-
ergy balance and expenditure raises the intriguing possibility
that caveolin-3 may play a role during increased lipid utiliza-
tion and lipolysis. This is supported by reports showing that a
caveolin-3 mutant associates with lipid droplets in cultured
cells (34, 35).
FIG. 9. Schematic representation of the regulatory cross-talk
between the adrenergic signaling pathway and the nuclear hor-
mone receptor NR4A1/Nur77 in skeletal muscle. The brain re-
sponds to signals from the diet, and neural infrastructure controlling
energy expenditure is stimulated, which increases sympathetic activity.
The nuclear hormone receptor, NR4A1/Nur77, is involved in mediating
the adrenergic response in skeletal muscle. This underscores the phys-
iological importance of regulatory cross-talk between these two critical
pathways in energy homeostasis.
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The fact that the expression of this subgroup of genes regulat-
ing energy expenditure and balance is dependent on Nur77 ex-
pression, and the remarkable sensitivity of Nur77 expression to
isoprenaline highlights the crucial role of Nur77 in energy home-
ostasis (see Fig. 9) and identifies Nur77 as a promising thera-
peutic target in the treatment of obesity. Skeletal muscle is
rapidly emerging as a critical target tissue in the battle against
obesity, type II diabetes, dyslipidemia, syndrome X, and athero-
sclerosis. For example, NRs such as LXR, PPAR, -/, and - in
skeletal muscle have been shown to be involved in enhancing the
insulin-stimulated glucose disposal rate, decreasing triglycer-
ides, and increasing lipid catabolism, cholesterol efflux, and
plasma high density lipoprotein C levels (12, 14, 17, 31, 32).
Hence, orphan NRs (for example, Nur77) that regulate energy
balance in skeletal muscle have enormous pharmacological util-
ity for the treatment of obesity. In conclusion, we suggest that in
skeletal muscle cells, Nur77 programs a cascade of gene expres-
sion designed to regulate energy expenditure in this major mass
lean tissue. Finally, we surmise that Nur77 agonists may have
therapeutic utility in the treatment of metabolic diseases includ-
ing type II diabetes and obesity.
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